MYO6 and gastric cancer: We found that the abnormal expression of MYO6 in GC was the result of miR-143 and miR-145 dysregulation, as supported by the following: (1) MYO6 was inversely expressed with miR-143 and miR-145 in GC, (2) miR-143 and miR-145 directly targeted MYO6 via binding to its 3′-UTR and (3) restoration of MYO6 canceled the migration-suppressive effects induced by miR-143 and/or miR-145.